Immune-Mediated Organ-Specific Reactions to COVID-19 Vaccines: A Retrospective Descriptive Study

被引:2
|
作者
Ruiz-Fernandez, Carmen [1 ]
Cuesta, Ricardo [1 ]
Martin-Lopez, Susana [2 ]
Guijarro, Javier [2 ]
de las Huertas, Arturo Lopez Gomez [2 ]
Urroz, Mikel [2 ]
Miguel-Berenguel, Laura [1 ]
Gonzalez-Munoz, Miguel [1 ]
Ramirez, Elena [2 ]
机构
[1] La Paz Univ Hosp IdiPAZ, Immunol Dept, Madrid 28046, Spain
[2] Univ Autonoma Madrid, La Paz Univ Hosp IdiPAZ, Fac Med, Clin Pharmacol Dept, Madrid 28046, Spain
关键词
COVID-19; vaccines; adverse drug reactions; delayed hypersensitivity reactions; causality algorithms; lymphocyte transformation test; POLYETHYLENE-GLYCOLS; CAUSALITY ASSESSMENT; HYPERSENSITIVITY; ALLERGY;
D O I
10.3390/ph16050720
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Severe acute respiratory syndrome coronavirus 2 caused the global COVID-19 pandemic and public health crisis, and it led to the rapid development of COVID-19 vaccines, which can cause rare and typically mild hypersensitivity reactions (HRs). Delayed HRs to COVID-19 vaccines have been reported, and the excipients polyethylene glycol (PEG)2000 and polysorbate 80 (P80) are the suspected culprits. Skin patch tests do not help in diagnosing delayed reactions. We aimed to perform lymphocyte transformation tests (LTT) with PEG2000 and P80 in 23 patients with suspected delayed HRs. Neurological reactions (n = 10) and myopericarditis reactions (n = 6) were the most frequent complications. Seventy-eight percent (18/23) of the study patients were admitted to a hospital ward, and the median time to discharge was 5.5 (IQR, 3-8) days. Some 73.9% of the patients returned to baseline condition after 25 (IQR, 3-80) days. LTT was positive in 8/23 patients (5/10 neurological reactions, 2/4 hepatitis reactions and 1/2 rheumatologic reactions). All myopericarditis cases had a negative LTT. These preliminary results indicate that LTT with PEGs and polysorbates is a useful tool for identifying excipients as causal agents in HRs to COVID-19 vaccines and can play an important role in risk stratification in patients with HRs.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Effectiveness of COVID-19 vaccination in immune-mediated inflammatory diseases
    Sparks, Jeffrey A.
    Singh, Namrata
    Wallace, Zachary S.
    LANCET RHEUMATOLOGY, 2022, 4 (06): : E380 - E382
  • [32] Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients
    Goonewardena, Sascha N.
    Grushko, Olga G.
    Wells, Joanna
    Herty, Lauren
    Rosenson, Robert S.
    Haus, Jacob M.
    Hummel, Scott L.
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (02) : 307 - 313
  • [33] Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients
    Sascha N. Goonewardena
    Olga G. Grushko
    Joanna Wells
    Lauren Herty
    Robert S. Rosenson
    Jacob M. Haus
    Scott L. Hummel
    Cardiovascular Drugs and Therapy, 2023, 37 : 307 - 313
  • [34] Immune-mediated liver injury following COVID-19 vaccination
    Georgios Schinas
    Eleni Polyzou
    Vasiliki Dimakopoulou
    Stamatia Tsoupra
    Charalambos Gogos
    Karolina Akinosoglou
    World Journal of Virology, 2023, (02) : 100 - 108
  • [35] COVID-19 Breakthrough Infections in Immune-Mediated Inflammatory Diseases: Data from the SUCCEED (Safety and Immunogenicity of COVID-19 Vaccines in Systemic Autoimmune-Mediated Inflammatory Diseases) Study
    Tan, Jeremiah
    Bernatsky, Sasha
    Lee, Jennifer L. F.
    Fortin, Paul R.
    Dayam, Roya M.
    Gingras, Anne-Claude
    Colmegna, Ines
    Bowdish, Dawn M. E.
    Berger, Claudie
    Chan, Dora
    Larche, Maggie J.
    Richards, Dawn P.
    Gonzalez Arreola, Lourdes
    Hitchon, Carol A.
    Lalonde, Nadine
    Avina-Zubieta, J. Antonio
    VACCINES, 2025, 13 (02)
  • [36] IMMUNE-MEDIATED DISEASES (IMID) AND CORONAVIRUS DISEASE 2019 (COVID-19): RESULTS FROM AN OBSERVATIONAL RETROSPECTIVE MULTICENTER STUDY
    Dos-Santos, R.
    Calvino, C.
    Baston, I.
    Ferreiro, R.
    Montero, F.
    Gonzalez, C.
    Marin-Jimenez, I.
    Barreiro-de-Acosta, M.
    Perez-Pampin, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 916 - 917
  • [37] Impact of COVID-19 Pandemic on Initiation of Immunosuppressive Treatment in Immune-Mediated Inflammatory Diseases in Austria: A Nationwide Retrospective Study
    Kutschera, Maximilian
    Ritschl, Valentin
    Reichardt, Berthold
    Stamm, Tanja
    Kiener, Hans
    Maier, Harald
    Reinisch, Walter
    Benka, Bernhard
    Novacek, Gottfried
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (18)
  • [38] The effects of methotrexate on the immune responses to the COVID-19 vaccines in the patients with immune-mediated inflammatory disease: A systematic review of clinical evidence
    Al-Haideri, Maysoon T.
    Mannani, Reza
    Kaboli, Roghayyeh
    Gharebakhshi, Farshad
    Darvishzadehdeldari, Shahram
    Tahmasebi, Safa
    Faramarzi, Fatemeh
    Cotrina-Aliaga, Juan Carlos
    Khorasani, Sahar
    Alimohammadi, Mina
    Darvishi, Mohammad
    Akhavan-Sigari, Reza
    TRANSPLANT IMMUNOLOGY, 2023, 79
  • [39] Suspected adverse reactions to COVID-19 vaccines in a university hospital: A descriptive analysis
    Rodriguez Cumplido, Dolores
    Ordonez Rufat, Pilar
    Llop Rius, Roser
    Videla Ces, Sebastian
    Otero Gonzalez, Aurema
    Carnaval, Thiago
    Hereu Boher, Pilar
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 130 : 26 - 26
  • [40] Organ-specific or personalized treatment for COVID-19: rationale, evidence, and potential candidates
    Seyedeh Zahra Mousavi
    Mojdeh Rahmanian
    Ashkan Sami
    Functional & Integrative Genomics, 2022, 22 : 429 - 433